We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+2.06%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$342M
AUM Growth
+$4.53M
Cap. Flow
+$2.54M
Cap. Flow %
0.74%
Top 10 Hldgs %
27.24%
Holding
105
New
9
Increased
44
Reduced
37
Closed
6

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$8.51M
2
UHS icon
Universal Health Services
UHS
+$7.3M
3
ABBV icon
AbbVie
ABBV
+$6.16M
4
RAD
Rite Aid Corporation
RAD
+$5.54M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$4.74M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$10.6M
2
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$8.41M
3
CELG
Celgene Corp
CELG
+$6.93M
4
BIIB icon
Biogen
BIIB
+$6.92M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$5.75M

Sector Composition

Rank Sector Weight
1 Healthcare 78.72%
2 Financials 1.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MD icon
51
Pediatrix Medical
MD
$2.2B
$2.41M 0.71%
44,000
+14,000
+47% +$794K
CERN
52
DELISTED
Cerner Corp
CERN
$2.38M 0.7%
40,000
+5,000
+14% +$281K
PODD icon
53
Insulet
PODD
$9.79B
$2.32M 0.68%
62,911
-37,089
-37% -$1.35M
ARIA
54
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$2.28M 0.67%
423,000
+33,000
+8% +$193K
IONS icon
55
Ionis Pharmaceuticals
IONS
$9.4B
$2.25M 0.66%
58,000
+22,000
+61% +$780K
CYBX
56
DELISTED
CYBERONICS INC
CYBX
$2.2M 0.64%
43,000
-31,000
-42% -$1.79M
HOLX
57
DELISTED
Hologic
HOLX
$2.19M 0.64%
90,000
+17,000
+23% +$429K
AEGR
58
DELISTED
Aegerion Pharmaceuticals
AEGR
$2.17M 0.64%
65,000
+23,069
+55% +$716K
PRXL
59
DELISTED
Parexel International Corp
PRXL
$2.15M 0.63%
34,000
-21,000
-38% -$1.2M
ELGX
60
DELISTED
Endologix Inc
ELGX
$2.12M 0.62%
20,000
-500
-2% -$69.7K
AMSG
61
DELISTED
Amsurg Corp
AMSG
$2.12M 0.62%
42,300
+15,000
+55% +$749K
OREX
62
DELISTED
Orexigen Therapeutics, Inc.
OREX
$2.1M 0.62%
49,400
+19,380
+65% +$1.04M
EW icon
63
Edwards Lifesciences
EW
$51.7B
$2.04M 0.6%
120,000
-90,000
-43% -$1.42M
ITCI
64
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.04M 0.6%
149,000
+50,731
+52% +$762K
CFN
65
DELISTED
CAREFUSION CORPORATION
CFN
$2.04M 0.6%
45,000
-5,000
-10% -$225K
RVNC
66
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.04M 0.6%
105,255
+23,255
+28% +$606K
ESPR
67
DELISTED
Esperion Therapeutics
ESPR
$2.03M 0.59%
+82,921
New +$1.32M
HPTX
68
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$2.03M 0.59%
80,369
+10,000
+14% +$248K
ACHN
69
DELISTED
Achillion Pharmaceuticals
ACHN
$2M 0.58%
200,000
-130,000
-39% -$1.21M
CI icon
70
Cigna
CI
$74.6B
$2M 0.58%
22,000
-33,000
-60% -$3.08M
INFI
71
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.99M 0.58%
148,000
+34,727
+31% +$414K
CPHD
72
DELISTED
Cepheid Inc
CPHD
$1.98M 0.58%
45,000
+10,000
+29% +$422K
LLY icon
73
Eli Lilly
LLY
$1.06T
$1.95M 0.57%
30,000
-14,500
-33% -$918K
IMGN
74
DELISTED
Immunogen Inc
IMGN
$1.91M 0.56%
180,000
+81,298
+82% +$920K
NUVA
75
DELISTED
NuVasive, Inc.
NUVA
$1.88M 0.55%
54,000
-22,000
-29% -$783K
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2014 Portfolio in Review

As of Q3 2014, Rhenman & Partners Asset Management held 105 positions worth $342M, up 1.3% from $337M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management's Q3 2014 filing shows 9 new, 44 increased, 37 reduced and 6 closed positions. Its largest new stake was Medtronic: 133,800 shares worth $6.87M. The largest sale was Gilead Sciences, an estimated $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 85% a quarter earlier, followed by Financials.

  • Rhenman & Partners Asset Management's largest Q3 2014 buy was Medtronic: 133,800 shares worth $6.87M.
  • Rhenman & Partners Asset Management added most to Universal Health Services in Q3 2014, an estimated $7.3M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2014 reduction was Gilead Sciences, cutting an estimated $10.6M.
  • Rhenman & Partners Asset Management fully exited Myriad Genetics in Q3 2014, selling an estimated $3.11M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $342M portfolio in Q3 2014.
  • Rhenman & Partners Asset Management opened 9 new positions and closed 6 in Q3 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 1.3% quarter-over-quarter to $342M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2014, filed 3 Nov 2014.